|
|
Volumn 25, Issue 2, 2002, Pages 194-197
|
|
Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer
|
|
Author keywords
5 Fluorouracil (5 FU); Breast cancer, metastatic; Paclitaxel
|
|
Indexed keywords
DOXORUBICIN;
FLUOROURACIL;
PACLITAXEL;
ADULT;
AGED;
ANAPHYLAXIS;
ARTICLE;
BLOOD TOXICITY;
BREAST CANCER;
BREAST METASTASIS;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
CANCER RECURRENCE;
CANCER SURVIVAL;
CENTRAL VENOUS CATHETER;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DISEASE COURSE;
DOSE RESPONSE;
DRUG HYPERSENSITIVITY;
DRUG INFUSION;
DRUG RESPONSE;
DRUG TOLERABILITY;
DYSERYTHROPOIESIS;
FATIGUE;
HUMAN;
INFUSION PUMP;
MUCOSA INFLAMMATION;
NAUSEA;
NEUROTOXICITY;
PHASE 2 CLINICAL TRIAL;
QUALITY OF LIFE;
SURVIVAL TIME;
THROMBOCYTOPENIA;
VOMITING;
ADULT;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
FLUOROURACIL;
HUMANS;
INFUSION PUMPS;
MIDDLE AGED;
NEOPLASM METASTASIS;
NEOPLASM RECURRENCE, LOCAL;
PACLITAXEL;
QUALITY OF LIFE;
SURVIVAL ANALYSIS;
|
|
EID: 0036220268
PISSN: 02773732
EISSN: None
Source Type: Journal
DOI: 10.1097/00000421-200204000-00020 Document Type: Article |
|
Times cited : (6)
|
|
References (6)
|
